{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Lexington&page=12&state=Kentucky", "query": { "state": "Kentucky", "city": "Lexington", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 4513, "total_pages": 452, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Lexington&page=13&state=Kentucky&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Lexington&page=11&state=Kentucky&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T15:01:29.629Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05391126", "title": "GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colorectal Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Reema A. Patel", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2022-09-28", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-12-16", "last_synced_at": "2026-10-18T15:01:29.629Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05391126" }, { "nct_id": "NCT05346835", "title": "Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cilta-cel OOS Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-18T15:01:29.629Z", "location_count": 137, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Goodyear, Arizona + 96 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05346835" }, { "nct_id": "NCT03086343", "title": "A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis (RA)" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion)", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo for upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 657, "start_date": "2017-05-09", "completion_date": "2023-06-06", "has_results": true, "last_update_posted_date": "2024-07-18", "last_synced_at": "2026-10-18T15:01:29.629Z", "location_count": 44, "location_summary": "Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03086343" }, { "nct_id": "NCT07573215", "title": "Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "PDAC", "PDAC - Pancreatic Ductal Adenocarcinoma", "Metastatic Pancreas Adenocarcinoma", "Pancreatic Cancer", "Pancreatic Cancer Metastatic", "Pancreatic Adenocarcinoma Metastatic", "Pancreatic Adenocarcinoma", "Pancreatic Adenosquamous Carcinoma" ], "interventions": [ { "name": "daraxonrasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-18T15:01:29.629Z", "location_count": 256, "location_summary": "Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 198 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Fort Payne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07573215" }, { "nct_id": "NCT05316155", "title": "Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Muscle Invasive Bladder Neoplasms" ], "interventions": [ { "name": "Erdafitinib Intravesical Delivery System", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2022-04-11", "completion_date": "2029-07-24", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-18T15:01:29.629Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Largo", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05316155" }, { "nct_id": "NCT00849017", "title": "Safety and Efficacy Study of Albiglutide in Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "albiglutide", "type": "BIOLOGICAL" }, { "name": "albiglutide uptitration", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 309, "start_date": "2009-01", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2017-01-09", "last_synced_at": "2026-10-18T15:01:29.629Z", "location_count": 247, "location_summary": "Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more", "locations": [ { "city": "Alabaster", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00849017" }, { "nct_id": "NCT03737994", "title": "Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Brigatinib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ceritinib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Ensartinib", "type": "DRUG" }, { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-07-25", "completion_date": "2026-03-17", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-18T15:01:29.629Z", "location_count": 491, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 341 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03737994" }, { "nct_id": "NCT05078437", "title": "Assessment of Medication Optimization in Rural Kentucky Appalachian Patients With Mild Cognitive Impairment or Dementia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dementia", "Mild Cognitive Impairment" ], "interventions": [ { "name": "Medication therapy management", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Daniela Moga", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 16, "start_date": "2021-10-14", "completion_date": "2023-05-14", "has_results": true, "last_update_posted_date": "2024-08-23", "last_synced_at": "2026-10-18T15:01:29.629Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05078437" }, { "nct_id": "NCT00003828", "title": "S9804: Vinorelbine in Treating Patients With Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 24, "start_date": "1999-05", "completion_date": "2004-03", "has_results": false, "last_update_posted_date": "2012-08-22", "last_synced_at": "2026-10-18T15:01:29.629Z", "location_count": 86, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003828" }, { "nct_id": "NCT02438722", "title": "S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Recurrent Non-Small Cell Lung Carcinoma", "Stage IV Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Afatinib Dimaleate", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 174, "start_date": "2015-05-07", "completion_date": "2026-04-17", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-10-18T15:01:29.629Z", "location_count": 638, "location_summary": "Fort Smith, Arkansas • Hot Springs, Arkansas • Jonesboro, Arkansas + 406 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02438722" } ] }